Asset / Drug

Apotex

Drug and asset intelligence for Apotex with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Mechanism of action

Topical Immunomodulator

RegulatoryJuly 1, 2026

Apotex Inc. has submitted a supplemental Abbreviated New Drug Application (ANDA091308) for Imiquimod.

CompetitiveJune 22, 2026

Apotex has submitted an Abbreviated New Drug Application (ANDA) for Tofacitinib Citrate, currently under standard review.

No catalysts indexed for this entity yet.

Topline Data

Monitor the timeline for the FDA's final decision and any subsequent market entry by Apotex.

July 3, 2026 · N/A

Topline Data

Monitor the FDA's review timeline and any subsequent approval announcements for this supplemental application.

July 1, 2026 · N/A

Topline Data

Monitor the review progress of ANDA220458 and any subsequent approvals or market entries by Apotex.

June 22, 2026 · N/A

No related entities indexed yet.

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.